MediWound (MDWD) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
MediWound Reports Second Quarter 2015 Financial Results
August 3, 2015 4:34 PM EDTYAVNE, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and six months ended June 30, 2015.
Highlights of the second quarter of 2015 and recent weeks include:
Increasing use and adoption of NexoBrid® in key European markets Advancement of U.S. Phase 3 clinical trial of NexoBrid® to treat severe burns Approval by the Israeli Office of the Chief Scientist of first grant to support... More